IO Biotech Reports Its Off-The-Shelf Therapeutic Cancer Vaccine, IO102-IO103, In Combination With KEYTRUDA Demonstrated Promising Activity With An Overall Response Rate Of 55% Unconfirmed/48% Confirmed, Disease Control Rate Of 81%, And ~50% Of...
IO Biotech Reports Its Off-The-Shelf Therapeutic Cancer Vaccine, IO102-IO103, In Combination With KEYTRUDA Demonstrated Promising Activity With An Overall Response Rate Of 55% Unconfirmed/48% Confirmed, Disease Control Rate Of 81%, And ~50% Of...
-- Pre-clinical data for IO Biotech's second T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive tumor-associated macrophages (TAMs) --IO Biotech Reports Its Off-The-Shelf Therapeutic Cancer Vaccine, IO102-IO103, In Combination With KEYTRUDA Demonstrated Promising Activity With An Overall Response Rate Of 55% Unconfirmed/48% Confirmed, Disease Control Rate Of 81%, And ~50% Of Patients Without Disease Progression At 12 Months; Median Duration Of Response Not Reached
IO Biotech報告，其現貨治療癌症生物-疫苗IO102-IO103與KEYTRUDA聯合應用展現出有前途的活性，總體響應率爲55％未確認/確認48％，疾病控制率爲81％，大約50％的患者在12個月內沒有疾病進展；中位響應持續時間尚未達到
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 months; median duration of response not reached --
-- 在第一線治療的轉移性非小細胞-5g肺癌（NSCLC）患者中，IO102-IO103與Keytruda聯合應用展現出有前途的活性，總體響應率爲55％未確認/確認48％，疾病控制率爲81％，約50％的患者在12個月內沒有疾病進展；中位響應持續時間尚未達到 --
-- Safety profile consistent with prior studies with the combination, showing no unexpected toxicities compared to anti-PD1 monotherapy, and low-grade transient injection site reactions as the most common treatment related adverse event --
-- 安全概況與之前研究與該組合一致，與PD1單藥療法相比，未顯示出意外毒性，最常見的治療相關不良事件是低級別瞬間注射部位反應 --
-- The data from this NSCLC cohort combined with the recent positive squamous cell carcinoma of the head and neck (SCCHN) cohort data presented at ESMO 2024 and previously reported positive Phase 1/2 study in melanoma demonstrate the potential of IO102-I0103 to be effective in broad patient populations --
-- 該NSCLC隊列的數據與最近在ESMO 2024展示的頭頸部鱗狀細胞癌（SCCHN）隊列數據以及此前在黑色素瘤中報告的積極1/2期研究相結合，顯示了IO102-I0103在廣泛患者人群中高效的潛力 --
-- Pre-clinical data for IO Biotech's second T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive tumor-associated macrophages (TAMs) --
-- IO生物的第二個T-win疫苗候選，IO112靶向精氨酸酸化酶1，顯示出在腫瘤微環境（TME）中動態變化的抗腫瘤活性，這種變化是由疫苗靶向調節免疫抑制性腫瘤相關巨噬細胞（TAMs）所驅動的 --
-- Data presented at the Society for Immunotherapy of Cancer's Annual Meeting --
-- 在癌症免疫治療學會年會上展示的數據 --
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune modulating therapeutic cancer vaccines, announced data from the NSCLC cohort in the company's Phase 2 basket trial of IO102-IO103, the company's lead investigational candidate, given in combination with Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy KEYTRUDA (pembrolizumab) (IOB-022/KN-D38). These data, as well as new pre-clinical data from IO Biotech's second vaccine candidate, IO112, will be presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston on November 8-10, 2024.
2024年11月7日紐約（全球新聞社）-- IO生物（納斯達克：IOBT），一家臨床階段的生物製藥公司，正在開發新型的現貨，調節免疫的治療性癌症生物-疫苗，宣佈在公司的IO102-IO103相位2籃子試驗中，該公司的主要研究候選者，與Merck（在美國和加拿大以外地區稱爲MSD）的PD-1療法KEYTRUDA（pembrolizumab）（IOb-022/KN-D38）聯合給藥上的NSCLC隊列的數據，這些數據以及IO生物第二個疫苗候選，IO112的新的臨床前數據，將在2024年11月8-10日在休斯頓舉行的癌症免疫治療學會的第39屆年會（SITC 2024）上進行介紹。
譯文內容由第三人軟體翻譯。
